Modulating epigenetic modifications for cancer therapy (Review)
Por:
Castro-Munoz, Leonardo Josue, Ulloa, Elenae Vazquez, Sahlgren, Cecilia, Lizano, Marcela, de la Cruz-Hernandez, Erick, Contreras-Paredes, Adriana
Publicada:
1 mar 2023
Resumen:
Cancer is a global public health concern. Alterations in epigenetic
processes are among the earliest genomic aberrations occurring during
cancer development and are closely related to progression. Unlike
genetic mutations, aberrations in epigenetic processes are reversible,
which opens the possibility for novel pharmacological treatments.
Non-coding RNAs (ncRNAs) represent an essential epigenetic mechanism,
and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs
(epidrugs) are a group of promising target therapies for cancer
treatment acting as coadjuvants to reverse drug resistance in cancer.
The present review describes central epigenetic aberrations during
malignant transformation and explains how epidrugs target DNA
methylation, histone modifications and ncRNAs. Furthermore, clinical
trials focused on evaluating the effect of these epidrugs alone or in
combination with other anticancer therapies and other ncRNA-based
therapies are discussed. The use of epidrugs promises to be an effective
tool for reversing drug resistance in some patients with cancer.
Filiaciones:
Castro-Munoz, Leonardo Josue:
The Wistar Institute, Philadelphia, PA 19104, United States
Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
Ulloa, Elenae Vazquez:
Faculty of Science and Engineering/Cell Biology, University of Turku and Åbo Akademi University, Turku, 20500, Finland
Turku Bioscience, University of Turku and Åbo Akademi University, Turku, 20500, Finland
Univ Turku, Fac Sci & Engn Cell Biol, Turku 20500, Finland
Univ Turku, Turku Biosci, Turku 20500, Finland
Abo Akad Univ, Turku 20500, Finland
Sahlgren, Cecilia:
Faculty of Science and Engineering/Cell Biology, University of Turku and Åbo Akademi University, Turku, 20500, Finland
Turku Bioscience, University of Turku and Åbo Akademi University, Turku, 20500, Finland
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, 5600 MB, Netherlands
Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, 5600 MB, Netherlands
Univ Turku, Fac Sci & Engn Cell Biol, Turku 20500, Finland
Univ Turku, Turku Biosci, Turku 20500, Finland
Abo Akad Univ, Turku 20500, Finland
Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands
Eindhoven Univ Technol, Inst Complex Mol Syst, NL-5600 MB Eindhoven, Netherlands
Lizano, Marcela:
Unidad de Investigacion Biomedica en Cancer, Instituto Nacional de Cancerología, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, 14080, Mexico
Departamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico, 04510, Mexico
Univ Nacl Autonoma Mexico, Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City 14080, Mexico
Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Med Genom & Toxicol Ambiental, Mexico City 04510, Mexico
de la Cruz-Hernandez, Erick:
Laboratory of Research in Metabolic and Infectious Diseases, Multidisciplinary Academic Division of Comalcalco, Juarez Autonomous University of Tabasco, Tabasco, Comalcalco, 86650, Mexico
Juarez Autonomous Univ Tabasco, Multidisciplinary Acad Div Comalcalco, Lab Res Metab & Infect Dis, Comalcalco 86650, Tabasco, Mexico
Contreras-Paredes, Adriana:
Unidad de Investigacion Biomedica en Cancer, Instituto Nacional de Cancerología, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, 14080, Mexico
Univ Nacl Autonoma Mexico, Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City 14080, Mexico
hybrid, Green Accepted, All Open Access; Hybrid Gold
|